Summarized by Masters of Longevity from Apollo Health Ventures.
The Series A extension brought total financing in the round to $75 million to advance investigational therapies for neurodegenerative and retinal diseases.
Key Takeaways
- Angelini Ventures and Apollo Health Ventures joined the investor syndicate.
- Proceeds support THN391 trials in Alzheimer’s disease and diabetic macular edema.
- THN391 remained investigational; the announcement did not establish clinical efficacy.
